Who are Placebo for levosimendan's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): epinephrine and levosimendan, Regular management+Levosimendan, Levosimendan Injection, Levosimontane injection, Levosimendan infusion, Simdax.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-for-levosimendan.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Placebo for levosimendan — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Placebo for levosimendan (Placebo for levosimendan) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcium sensitizer. Area: Cardiovascular.

phase 3 Calcium sensitizer Troponin C Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Placebo for levosimendan (Placebo for levosimendan) — Orion Corporation, Orion Pharma. Levosimendan is a calcium sensitizer that increases cardiac contractility without increasing oxygen demand.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Placebo for levosimendan TARGET	Placebo for levosimendan	Orion Corporation, Orion Pharma	phase 3	Calcium sensitizer	Troponin C
epinephrine and levosimendan	epinephrine and levosimendan	Federal University of Juiz de Fora	marketed	Inotropic agent combination	Adrenergic receptors (alpha-1, beta-1) and cardiac troponin C
Regular management+Levosimendan	Regular management+Levosimendan	Qilu Hospital of Shandong University	marketed	Calcium sensitizer / Inotropic agent	Cardiac troponin C
Levosimendan Injection	Levosimendan Injection	Peking University Third Hospital	marketed	Calcium sensitizer / inotropic agent	Cardiac troponin C; ATP-sensitive potassium channels
Levosimontane injection	Levosimontane injection	Qilu Hospital of Shandong University	marketed	Calcium sensitizer / inotropic agent	Cardiac troponin C; ATP-sensitive potassium channels
Levosimendan infusion	Levosimendan infusion	AHEPA University Hospital	marketed	Calcium sensitizer / inodilator	Cardiac troponin C; ATP-sensitive potassium channels
Simdax	Simdax	Yooyoung Pharmaceutical Co., Ltd.	phase 3		ATP-sensitive inward rectifier potassium channel 8, ATP-sensitive inward rectifier potassium channel 11, Troponin C, slow skeletal and cardiac muscles

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Calcium sensitizer class)

Orion Corporation, Orion Pharma · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo for levosimendan — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-for-levosimendan. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab